Author of

• 18973

  +

  P2.01 - Advanced NSCLC (ID 618)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/17/2017, 09:00 - 16:00, Exhibit Hall (Hall B + C)

  • 23189

    +

    P2.01-066 - Targeted Therapy for Lung Cancer: Liquid Biopsy or Tumor Sampling? A Case-Control Study (ID 9106)

    09:00 - 09:00  |  Presenting Author(s): Zhen-Yu Ding
    • Abstract
    • Slides

    Background:
    Liquid biopsy provides a valuable source to guide the targeted therapy for lung cancer. However, the comparison between the liquid biopsy or tumor sampling guided therapy was lacking. Here we performed a case-control study to compare the clinical outcome of these two strategies.
    
    Method:
    In this retrospective study, the admitted patients from Jan 2015 to Feb 2016 were screened through a pre-established database. Patients with metastatic, pathologically-confirmed, and treatment naïve non-small cell lung cancer who were prescribed with epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) from the guidance of liquid biopsy were enrolled (Liquid group). The mutation status in tumors was not mandatory. During the same period, patients medicated with TKI based on tumor samples were included in the Control group. They were enrolled in an age-, gender-, performance-matched manner.
    
    Result:
    We screened 536 patients and enrolled 26 patients in the Liquid group. Another 52 patients were enrolled in a 1:2 ratio in the Control group. In the Liquid group, a high consistence (84.6%) in EGFR mutation status between liquid and tumor was observed. The best response was partial response in 19 patients (73.1 %), and followed by stable disease in 6 patients (23.1 %). The median progression-free survival was 10.0 months (95%CI: 4.2-15.8 months). In the Control group, a similar disease control rate (81.2%, P=0.679) and comparable PFS (7.8 months, 95% CI: 7.1-10.4 months, P=0.798), HR=0.713, 95% CI: 0.321-1.195) was found. In the Liquid group, 3 of 4 patients with discordant results between tumor and liquid biopsy showed treatment responses favoring the liquid biopsy.
    
    Conclusion:
    This study provided direct evidence supporting the liquid biopsy for guiding the targeted therapy for lung cancer.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.